ReviewMedicina (Kaunas, Lithuania)2026
The Epigenetic Architecture of Classical Hodgkin Lymphoma: Lineage Erasure, Immune Escape, and Therapeutic Reprogramming.
Review in Medicina (Kaunas, Lithuania), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Classical Hodgkin lymphoma (cHL) is distinguished by a rare population of Hodgkin and Reed-Sternberg (HRS) cells that has largely extinguished its germinal center (GC) B-cell identity while maintaining survival, immune escape, and dependence on a highly organized tumor microenvironment (TME). This narrative review examines how interacting epigenetic mechanisms construct and stabilize this malignant state and evaluates whether it can be therapeutically reprogrammed. The relevant mechanistic and clinical literature available through 2026 was synthesized, encompassing lineage factor disruption, DNA methylation, histone modifications, Polycomb repression, chromatin-remodeling lesions, non-coding RNAs, antigen presentation, immune checkpoint regulation, and epigenetic therapies in cHL. Lineage erasure appears to be an actively maintained program produced by promoter hypermethylation, histone deacetylation, Polycomb-associated repression, altered histone demethylase activity, transcription factor antagonism, and somatic lesions affecting chromatin regulators. These mechanisms coexist with structural and transcriptional alterations involving antigen presentation and programmed death ligand 1/programmed death ligand 2 (PD-L1/PD-L2), while non-coding RNAs and extracellular vesicles provide an additional regulatory layer connecting HRS cells with immune and stromal components of the TME. Epigenetic repression is heterogeneous in its reversibility: partially methylated or deacetylated loci may remain pharmacologically responsive, whereas densely methylated, Polycomb-associated, or genetically entrenched states are less likely to be restored through isolated interventions. Histone deacetylase (HDAC) and DNA methyltransferase (DNMT) inhibitors can nevertheless alter tumor- and immune-related programs, supporting combinations with PD-1 blockade. Complete restoration of a physiological B-cell epigenome is unlikely; however, the HRS state remains therapeutically modifiable. Epigenetic therapy may therefore be most effective when used to reduce state stability and increase immune visibility rather than to achieve complete lineage reconstitution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.